Clinical Trial Update: Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors [Phase 1]

View source ↗

Summary

A Phase I clinical trial evaluating JYP0322 in ROS1 fusion-positive solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Cancer
• Lung Cancer

Drugs mentioned

• JYP0322

Snippet

Sponsor: Guangzhou JOYO Pharma Co., Ltd | Conditions: Protein Kinase Inhibitors, Other Protocol Specified Criteria | Phase 1 | Status: RECRUITING